18 results
8-K
EX-99.1
QNCX
Quince Therapeutics Inc
24 Jul 23
Entry into a Material Definitive Agreement
7:16am
treatment from FDA and EMA Leadership Luca Benatti: CEO Special protocol assessment (SPA) in place with FDA for single Phase 3 clinical trial of EryDex … to EryDel stockholders Governance & Leadership Structure Approvals & Closing David Lamond remains Chairperson EryDel to operate as wholly owned
PRE 14A
iiulfrqi73 nud6z
4 Apr 23
Preliminary proxy
4:33pm
8-K
EX-99.1
1p04e 8etfzfnl
10 May 22
Cortexyme Announces Agreement to Acquire Novosteo
8:08am
8-K
8c9feoi 70
10 Feb 21
Departure of Directors or Certain Officers
4:32pm
8-K
EX-99.1
it0si7vpk1hk7rc
12 May 20
Cortexyme Announces First Quarter 2020 Financial Results and Provides Business Update
4:45pm
DEF 14A
0ew74nxiuko w2hhggw
22 Apr 20
Definitive proxy
3:26pm
10-K
tzouw ue3
16 Mar 20
Annual report
4:16pm
424B4
ekgfnxd
9 May 19
Prospectus supplement with pricing info
5:14pm
S-1/A
09526p9ms1qttyip
16 Apr 19
IPO registration (amended)
6:04am
S-1
ckgg 0t9cvp2ep1epdxr
12 Apr 19
IPO registration
5:20pm
DRS
bjens g0o5eimh
4 Mar 19
Draft registration statement
12:00am
- Prev
- 1
- Next